Last reviewed · How we verify

Antibe Therapeutics Inc. — Portfolio Competitive Intelligence Brief

Antibe Therapeutics Inc. pipeline: 0 marketed, 0 filed, 0 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 3 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. American University of Beirut Medical Center · 1 shared drug class
  2. Amneal Pharmaceuticals, LLC · 1 shared drug class
  3. Apsen Farmaceutica S.A. · 1 shared drug class
  4. AstraZeneca · 1 shared drug class
  5. Behar, Caren, M.D. · 1 shared drug class
  6. Chinese University of Hong Kong · 1 shared drug class
  7. Generic (originally Syntex) · 1 shared drug class
  8. Allergan · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Antibe Therapeutics Inc.:

Cite this brief

Drug Landscape (2026). Antibe Therapeutics Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/antibe-therapeutics-inc. Accessed 2026-05-17.

Related